Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has ...

Shaw and Andrew Aguirre, an oncologist and pancreatic cancer researcher, are co-leading the newly launched Center for RAS Therapeutics, coordinating the prosecution of drugs aimed at KRAS ...

and experience the next generation of RAS-targeted drugs. Set to unite 150+ key leaders in biopharma and academia in Boston, this year’s event has a strong focus in tackling emerging resistance ...